Theratechnologies Company Executives
| TH Stock | CAD 1.70 0.02 1.19% |
Theratechnologies employs about 103 people. The company is managed by 25 executives with a total tenure of roughly 143 years, averaging almost 5.0 years of service per executive, having 4.12 employees per reported executive. Analysis of Theratechnologies' management performance can provide insight into the firm performance.
| Dawn Svoronos Chairman Independent Chairman of the Board |
| MarieNoel Colussi President Vice President - Finance |
Theratechnologies |
Theratechnologies Management Team Effectiveness
The company has return on total asset (ROA) of 0.1176 % which means that it generated a profit of $0.1176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (11.1686) %, meaning that it generated substantial loss on money invested by shareholders. Theratechnologies' management efficiency ratios could be used to measure how well Theratechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Equity is likely to grow to 1.39, while Return On Tangible Assets are likely to drop (0.44). At this time, Theratechnologies' Non Current Assets Total are very stable compared to the past year. As of the 2nd of December 2024, Other Assets is likely to grow to about 2.2 M, while Total Assets are likely to drop about 65.2 M.As of the 2nd of December 2024, Common Stock Shares Outstanding is likely to grow to about 55.9 M, though Net Loss is likely to grow to (40.4 M).
Theratechnologies Workforce Comparison
Theratechnologies is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,188. Theratechnologies holds roughly 103 in number of employees claiming about 9% of equities under Health Care industry.
Theratechnologies Profit Margins
The company has Profit Margin (PM) of (0.04) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.27 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.27.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.96 | 0.87 |
|
|
Theratechnologies Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Theratechnologies Price Series Summation is a cross summation of Theratechnologies price series and its benchmark/peer.
Theratechnologies Notable Stakeholders
A Theratechnologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Theratechnologies often face trade-offs trying to please all of them. Theratechnologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Theratechnologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Paul Lvesque | CEO President | Profile | |
| Paul Levesque | President, Chief Executive Officer, Director | Profile | |
| Dawn Svoronos | Independent Chairman of the Board | Profile | |
| MarieNoel Colussi | Vice President - Finance | Profile | |
| Jovan Antunovic | Senior Vice President and Chief Commercial Office | Profile | |
| Philippe Dubuc | Chief Financial Officer, Senior Vice President | Profile | |
| Pierre Perazzelli | Vice President - Pharmaceutical Development | Profile | |
| Christian Marsolais | Senior Vice President - Scientific Affairs and Alliances | Profile | |
| Jocelyn Lafond | Vice President - Legal Affairs, Corporate Secretary | Profile | |
| MBA MBA | Senior CFO | Profile | |
| Sheila Frame | Independent Director | Profile | |
| Gerald Lacoste | Independent Director | Profile | |
| Paul Pommier | Independent Director | Profile | |
| Gilles Cloutier | Independent Director | Profile | |
| Gary Littlejohn | Independent Director | Profile | |
| Dale Weil | Independent Director | Profile | |
| Conor Walshe | General Manager - Theratechnologies Europe Limited | Profile | |
| Andrew Molson | Independent Director | Profile | |
| LLB LLM | General Secretary | Profile | |
| LLB BA | VP Affairs | Profile | |
| Denis Boucher | Vice President - Communications and Corporate Affairs | Profile | |
| H MSc | Vice Resources | Profile | |
| John Leasure | Global Officer | Profile | |
| Elif McDonald | Director Relations | Profile | |
| Alain Trudeau | Independent Director | Profile |
About Theratechnologies Management Performance
The success or failure of an entity such as Theratechnologies often depends on how effective the management is. Theratechnologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Theratechnologies management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Theratechnologies management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | 1.32 | 1.39 |
Theratechnologies Workforce Analysis
Traditionally, organizations such as Theratechnologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Theratechnologies within its industry.Theratechnologies Manpower Efficiency
Return on Theratechnologies Manpower
| Revenue Per Employee | 793.8K | |
| Revenue Per Executive | 3.3M | |
| Net Loss Per Employee | 232.6K | |
| Net Loss Per Executive | 958.3K | |
| Working Capital Per Employee | 155.4K | |
| Working Capital Per Executive | 640.1K |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theratechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Theratechnologies Stock, please use our How to Invest in Theratechnologies guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.